Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.

@article{CombazLair2016ImmuneBP,
  title={Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.},
  author={Christelle Combaz-Lair and Françoise B Galateau-Sall{\'e} and Anne McLeer-Florin and Nolwenn Le Stang and Laurence David-Boudet and Mickael Duruisseaux and Gilbert Ferretti and Elisabeth M Brambilla and Serge J. Lebecque and Sylvie Lantu{\'e}joul},
  journal={Human pathology},
  year={2016},
  volume={52},
  pages={9-18}
}
Malignant pleural mesothelioma (MPM) is an aggressive tumor with no effective therapy. However PD-L1/PD-1 immunity checkpoint therapies gave encouraging results; TLR3 is a programmed death factor, which triggering up-regulates PD-L1. As PD-1/PD-L1 blocking antibodies could restore antitumor immune responses alone or in combination with TLR3 agonists, we investigated PD-L1/PD-1 and TLR3 expressions in MPM to select patients for immunotherapy. Sixty-eight pleural surgical specimens, including 58… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 7 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2018

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2018

TRAIL, Fas Ligand, TNF and TLR3 in Cancer

Resistance to Targeted Anti-Cancer Therapeutics • 2017
View 3 Excerpts

Similar Papers

Loading similar papers…